25 Years of Trust, Quality, and Health: SFI Health™ celebrates Equazen® milestone, the brand of food supplements developed to support cognitive needs
26.3.2025 08:00:00 CET | Business Wire | Press release
- From a pioneering intuition on the benefits of essential fatty acids for the human brain to becoming a global brand trusted by families and healthcare professionals
SFI Health™ is proud to celebrate the 25th anniversary of Equazen®, a globally recognized, science-based food supplement designed to nourish, enhance, and support the brain's potential. Since its market debut in 2000, Equazen® has remained committed to innovation and pharma-quality standards, establishing itself as a leading brand in cognitive health supplements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326323152/en/
Discover Equazen® comprehensive range: multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers. For more info visit www.equazen.com
The story of Equazen® began in 1999 in the UK with Prof. Horrobin’s groundbreaking research. Guided by his intuition, he researched certain pediatric cognitive function disorders stemming from a lack of essential fatty acids and their precursors. This insight led to the development of the first Equazen® product, originally known as Eye Q.
The product featured a unique combination of essential fatty acids, setting the foundation for Equazen®’s evolution while aligning with the company’s core philosophy: to harness the power of naturally sourced ingredients and adopt a pharma-quality approach to food supplements.
Since the publication of its first clinical evidence in 2005, Equazen® has been supported by over two decades of clinical trials. As a result, the brand is trusted globally by business partners, families and healthcare professionals to enhance learning capabilities, concentration, and overall cognitive well-being.
At the same time, Equazen® has evolved into multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers.
One of the latest innovations is Equazen® Jelly, which combines the unique blend of essential fatty acids with a fruity flavor designed to appeal to picky eaters. Additionally, its patent-protected technology ensures the jelly is easy to swallow and promotes better natural absorption.
Matthew Brabazon, GM of SFI Heath™ EMEA, the regional entity of SFI Health™, commented: “It’s been an incredible journey watching Equazen® grow over the past 25 years to become a trusted brand globally. Looking ahead, we remain focused on the future and have exciting plans to continue bringing innovation to the market.”
Zbyszek Czop, Managing Director of Qpharma Sp. z o.o., distributor of Equazen® in Poland said: “Earning the trust of doctors through the positive results of clinical studies on Equazen® is incredibly gratifying. Healthcare professionals now believe that Equazen® can make a meaningful difference for children, particularly those with behavioral disorders.”
Kirsten Jorsal, Founder of Novasel EU,distributor of Equazen® in Denmark added: “Equazen® is a unique fatty acid supplement, distinguished by its balanced blend of polyunsaturated fatty acids, with a notably higher EPA content compared to DHA. Along with its strong clinical documentation, it stands apart from other fish oil supplements. Working with this product for so many years has been both rewarding, and receiving feedback from satisfied families has been truly fulfilling.”
A deep knowledge of consumers’ needs continues to guide the brand and inspires future innovations. The Equazen® range is proudly available in 30 countries across all continents, and the company is dedicated to expanding its reach, ensuring more consumers worldwide can benefit from its offerings.
About SFI Health™
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information go to sfihealth.com or follow us SFI Health on LinkedIn.
About Equazen®
Equazen® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages.
Each product of the Equazen® range contains a balanced unique combination of essential fatty acids (Omega 3 and Omega 6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.
Equazen® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.
Currently marketed in 30 countries globally, Equazen® is widely recommended by healthcare professionals and trusted by families for the last 25 years.
Equazen® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.
For more info visit www.equazen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326323152/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
i2c Named Finalist for Best Security or Anti-Fraud Development at Card & Payments Awards Middle East 202612.2.2026 15:00:00 CET | Press release
i2c’s AI-driven Fraud Risk Management solution recognized for delivering impactful results for Middle East clients i2c Inc., a global financial technology innovator, has been named a finalist in the Best Security or Anti-Fraud Development category at The Card & Payments Awards Middle East 2026. The region’s premier awards program recognizes organizations that deliver practical, high-impact innovations to strengthen payment security and protect customers in one of the world’s fastest-growing digital payments markets. i2c was recognized for its AI-driven Fraud Risk Management solution, embedded directly within its unified banking and payments platform and operating in real time at the point of transaction authorization—an increasingly critical capability as digital payments scale across Middle East markets. By evaluating risk at the moment a payment is initiated, rather than after funds are approved, the solution enables earlier detection of fraudulent activity while preserving approval
SLB Awarded Multiple Offshore Drilling Contracts by Mubadala Energy for Tangkulo Deepwater Development in Indonesia12.2.2026 14:00:00 CET | Press release
Contracts support offshore gas development with first gas targeted before end of 2028 Global energy technology company SLB (NYSE: SLB) has been awarded multiple offshore drilling services contracts by Mubadala Energy, the Abu Dhabi headquartered international energy company, for the Tangkulo natural gas deepwater development and associated exploration and appraisal drilling activities in the Andaman Sea, offshore Indonesia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212809124/en/ The project will leverage SLB’s offshore and deepwater technologies, including real-time downhole monitoring, to reduce operational risk, improve well placement and strengthen project economics. Under the awards, SLB will work with Mubadala Energy to deliver integrated drilling and well services across the full well life cycle. The scope includes directional drilling, drilling fluids, cementing, wireline, slickline, coiled tubing, well testin
Align Partners Issues Formal Shareholder Proposals to Dentium12.2.2026 13:43:00 CET | Press release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Dentium Co., Ltd. (“Dentium” or the “Company”), has submitted formal shareholder proposals for inclusion in the agenda of Dentium’s upcoming 26th Annual General Meeting (“AGM”), urging the Company to strengthen governance practices and improve capital allocation discipline. Align Partners noted that, given shareholder proposals will be presented at this year’s AGM, Dentium should follow the Korea Exchange (KRX) Corporate Governance Key Indicators by publishing the AGM convocation notice at least four weeks prior to the meeting date and adopting an electronic voting system to enhance shareholder participation. Dentium is widely recognized as a global leader in the dental implant industry, supported by superior technology and more than 23 years of long-term clinical data. Despite this strong positioning, Align Partners believes the Company continues to trade at a meaningful discount. As of February 11, 2026, Dent
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to SoluM12.2.2026 13:42:00 CET | Press release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of SoluM Co., Ltd. (“SoluM” or the “Company”), has submitted formal shareholder proposals for inclusion in the agenda of SoluM’s 2026 Annual General Meeting (“AGM”) and issued its first public shareholder letter to the Company’s Board of Directors. Align Partners requested that SoluM’s Board and management provide a public written response to the shareholder letter by the AGM convocation notice deadline ahead of the March 2026 meeting. The campaign reflects Align Partners’ view that meaningful governance reforms and strategic focus are urgently needed to unlock shareholder value. SoluM operates a high-growth Electronic Shelf Label (“ESL”) business with strong global positioning and attractive long-term market potential. Despite this, the Company’s share price has remained near historical lows since its listing. As of February 11, 2026, SoluM trades at a last-twelve-month EV/EBIT multiple of 28.9x, representing a s
GigaDevice Extends European Reach with SEMITRON Partnership for DACH region12.2.2026 10:52:00 CET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has entered into a distribution agreement with SEMITRON, a leading electronic component distributor that specializes with a focus on the DACH region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203746978/en/ Under the terms of the deal, SEMITRON is set to supply both GigaDevice's leading Flash, MCU, power and sensor lines in conjunction with field application engineering support to customers in the industrial, automotive and communication technology sectors. In particular, SEMITRON offers professional test house services, technical know-how and local on-the-ground expertise and support. The partnership further extends GigaDevice's reach into this major European market, with on the ground support in Germany, Austria, Switzerland. Jürgen Rohland, Managing Director of SEMITRON W. Röck Gmb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom